Drug intelligence / Profile preview

Kalm Patch

Development stage: Preclinical
Lead developer: KALM Therapeutics
Modality: Small Molecules
Administration: Transdermal

Overview

The Kalm Patch is a steroid-free transdermal patch developed by KALM Therapeutics for the treatment of mild to moderate eczema (atopic dermatitis) and psoriasis. It utilizes proprietary "Continuous Dose" technology to deliver a natural anti-inflammatory compound over a 24-hour period. Beyond drug delivery, the patch serves a physical protective function, shielding affected skin from scratching, infection, and moisture loss. The active ingredient is a natural compound intended to calm the immune response and potentially balance the skin microbiome, offering a gentler alternative to traditional topical steroids or immunosuppressants. The product is currently in the pre-clinical stage, supported by NIH SBIR funding to advance toward clinical trials.

Brand names: Kalm Patch

Beyond the preview

Go deeper on Kalm Patch.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Kalm Patch.

Explore the full profile